About
CTX Platforms is a biotechnology company rapidly advancing towards a disruptive targeted technology application for imaging and treatment of brain cancers and other non-CNS tumors.
The company is developing a theranostic system, potentially capable of imaging living brain tumors and treating brain cancer in children and adults with non-invasive magnetic fields heating technology. This novel technology is based on the sophisticated delivery of magnetic nanoparticles directly to their location in the brain and the induction of focal heat to destroy the cancer cells. Together with existing immunotherapy, this adjuvant treatment can potentially offer new hope for people with GBM.
CTX develops its proprietary particles under license from cutting edge technology and academic centers.
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is the primary focus of CTX Platforms' technology?
- CTX Platforms is developing a targeted technology for the imaging and treatment of brain cancers and other non-CNS tumors, utilizing a theranostic system.
- What is the core mechanism of CTX Platforms' theranostic system?
- The system uses magnetic nanoparticles delivered directly to brain tumors, which are then heated by non-invasive magnetic fields to destroy cancer cells.
- When was CTX Platforms founded?
- CTX Platforms was founded in March 2018.
- What is the current operational status of CTX Platforms?
- CTX Platforms is currently inactive, having ceased operations in July 2023.
- Where is CTX Platforms headquartered?
- CTX Platforms is headquartered in Be'er Sheva, Israel.
- What is the employee count of CTX Platforms?
- CTX Platforms has 1 employee.
- Who are the founders of CTX Platforms?
- The founders of CTX Platforms are Omer Porat and Hagay Shmuely.
- What is the current funding stage of CTX Platforms?
- CTX Platforms is in the Pre-Funding stage, with a total raised amount of $0 USD.
- Does CTX Platforms hold any patents?
- Yes, CTX Platforms holds 1 patent.